Form 4: Ultragenyx Pharmaceutical Inc. Executive Sells Shares to Cover Tax Obligations

Theodore Alan Huizenga, SVP and Chief Accounting Officer of Ultragenyx Pharmaceutical Inc., sold 91 shares of common stock on September 3, 2024, to cover tax withholdings related to vesting RSUs.

Summary

• On September 3, 2024, Theodore Alan Huizenga, the SVP and Chief Accounting Officer of Ultragenyx Pharmaceutical Inc., sold 91 shares of the company's common stock.
• The sale was executed at a price of $56.19 per share.
• This transaction was conducted to cover required tax withholdings due to the vesting of Restricted Stock Units (RSUs).
• Following the transaction, Huizenga beneficially owns 41,551 shares of Ultragenyx Pharmaceutical Inc.
• This total includes 276 shares acquired under the company's Amended and Restated 2014 Employee Stock Purchase Plan on April 30, 2024, and previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction (sale of shares for tax purposes) and doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Sales of shares by company executives are a common occurrence, often related to compensation and tax obligations. These transactions are closely monitored by investors for insights into management's perspective on the company's value and future prospects.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to have a significant effect given the small number of shares involved.

Key Dates